Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.54 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | ME2 | P23368 | 1/20 | 0.40 |
| ▸ | ME1 | P48163 | 1/20 | 0.40 |
| ▸ | ME3 | Q16798 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30354825 | 0.86 | AGXT (0.61) | AGXTCYP2A6ASIC3LOXL2APP | |
| SCHEMBL13960107 | 0.83 | AGXT (0.54) | AGXTCYP2A6ASIC3LOXL2CYP1A2 | |
| SCHEMBL5755606 | 0.83 | AGXT (0.57) | AGXTCYP2A6ASIC3LOXL2APP | |
| SCHEMBL3905670 | 0.82 | RAB9A (0.57) | AGXTCYP2A6ASIC3LOXL2LMNA | |
| SCHEMBL1746765 | 0.80 | FFAR1 (0.60) | — | |
| SCHEMBL5319433 | 0.77 | AGXT (0.72) | AGXTCYP2A6ASIC3LOXL2APP | |
| SCHEMBL1747331 | 0.77 | VDR (0.49) | AGXTADRB2PTGESALOX5PSEN1 | |
| SCHEMBL24130409 | 0.76 | MAPT (0.44) | AGXTCYP2A6ASIC3LOXL2LMNA | |
| Cyanide SCHEMBL25382329 | 0.76 | AGXT (0.49) | AGXTCYP2A6ASIC3LOXL2LMNA | |
| SCHEMBL2088811 | 0.74 | AGXT (0.68) | AGXTCYP2A6ASIC3LOXL2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613804-B2 | Treatment of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock | ENCYSIVE PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-0819125-B1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-18 | — | — | US | disclosed |
| US-6342610-B2 | COMPOUNDS SUCH AS N-(4-BROMO-3-METHYL-5-ISOXAZOLYL)-2-N-BENZYLBENZO(B)THIOPHENE-3-SUFONAMIDE ADMINISTERED AS ENDOTHELIN PEPTIDE RECEPTOR ANTAGONISTS | TEXAS BIOTECHNOLOGY CORP. | 2002-01-29 | — | — | US | disclosed |
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | disclosed |
| EP-1048657-A1 | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-11-02 | — | — | EP | disclosed |
| US-5962490-A | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | EDNRA, EDNRB, NPSR1 | AGXT 3004/4885CYP2A6 3363/4885ASIC3 1684/4885 |
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRB, EDNRA, ECE2 | AGXT 2818/4885CYP2A6 753/4885ASIC3 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.